SPD-502 is a glutamate antagonist with potential neuroprotective properties, particularly in cerebral ischemia; it selectively targets AMPA receptors with high affinity (IC50 = 0.043 μM) and competitively inhibits AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons; in vivo, SPD-502 effectively blocks AMPA-induced spike activity in the hippocampus following intravenous administration, significantly raises the seizure threshold in mice, and demonstrates potent protective effects against ischemia-induced damage in gerbil hippocampal neurons; these findings suggest that SPD-502 may be promising for the treatment of neurodegenerative diseases associated with glutamate excitotoxicity.